<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770559</url>
  </required_header>
  <id_info>
    <org_study_id>daimh-RAMPS</org_study_id>
    <secondary_id>No.2020-1-4011</secondary_id>
    <nct_id>NCT03770559</nct_id>
  </id_info>
  <brief_title>The Therapeutic Evaluation(Both Short-term and Long-term Outcome) of Minimal Invasive Radical Antegrade Modular Pancreatosplenectomy for Left-sided Pancreatic Cancer Patients</brief_title>
  <acronym>MIRROR</acronym>
  <official_title>Minimal Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy for Left-sided Pancreatic Cancer: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Municipal Health Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer is regarded as &quot;the king of cancer&quot;. It is extremely malignant, with a low&#xD;
      sensibility to chemotherapy and radiotherapy, and a poor prognosis. Surgical treatment is&#xD;
      very important for pancreatic cancer. Radical antegrade modular pancreatosplenectomy (RAMPS)&#xD;
      is a standard method for treating pancreatic cancer at the body and tail of pancreas. In the&#xD;
      same surgical approach, the investigators are going to compare and discuss the advantages of&#xD;
      laparoscopic and open RAMPS in the RCT study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open RAMPS is widely used now to treat pancreatic cancer at the body and tail of pancreas.&#xD;
      Meanwhile, laparoscopic surgery is proved to have many advantages in other operations.&#xD;
      According to primary retrospective study of open and laparoscopic RAMPS, there was no&#xD;
      statistically significant difference in the long-term follow-up situations between these two&#xD;
      groups, indicating the safety of both this two surgical approaches. The investigators would&#xD;
      like to promote a prospective RCT study, to give more evidences of the superiority of&#xD;
      laparoscopic RAMPS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The development of study model was divided into 2 parrallel groups( Minimal Invasive RAMPS vs. Open RAMPS) based on the certain surgical procedure underwent</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Posteroperative length of stay</measure>
    <time_frame>Until patients were discharged</time_frame>
    <description>The days between the postoperative day-1 to the date when patient was eligible to be discharged.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>more than 1 year</time_frame>
    <description>DFS means the survival duration after surgery without any evidence of recurrence and metastasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>more than 1 year</time_frame>
    <description>DFS means the survival duration after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>10 hours</time_frame>
    <description>Durtion of operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>During the surgery</time_frame>
    <description>blood loss volume during the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Until patients were discharged</time_frame>
    <description>VAS score to measure the degree of postoperative pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>III-IV grade postoperative complication ratio</measure>
    <time_frame>No less than 3 months.</time_frame>
    <description>The ratio between patients with complication(s) and total patients in each groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Open-RAMPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with pancreatic cancer treated by traditional open surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MI-RAMPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with pancreatic cancer treated by laparoscopic surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimal Invasive RAMPS</intervention_name>
    <description>Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery</description>
    <arm_group_label>MI-RAMPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open RAMPS</intervention_name>
    <description>Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery</description>
    <arm_group_label>Open-RAMPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years old and older;&#xD;
&#xD;
          2. Pathology diagnosed as pancreatic adenocarcinoma or suspect cancer mass at the&#xD;
             pancreatic body or tail;&#xD;
&#xD;
          3. Patients who are eligible and planned to be performed RAMPS procedure;&#xD;
&#xD;
          4. Resectable or borderline resectable tumor by preoperative evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with evidence of distant metastasis or advanced arterial invasion so that are&#xD;
             not able to continue radical surgery;&#xD;
&#xD;
          2. ASA≥4；&#xD;
&#xD;
          3. Patients who are not willing to be performed open and/or mi-RAMPS;&#xD;
&#xD;
          4. Not pancreatic adenocarcinoma by posteroperative pathology.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Menghua Dai, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>PUMCH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HANYU ZHANG, M.D.</last_name>
    <phone>01069152600</phone>
    <email>medzhy5813@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yatong Li, M.D.</last_name>
    <phone>861069155992</phone>
    <email>medzhy5813@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Menghua Dai, M.D.</last_name>
      <email>daimh@pumch.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg. 1996 Sep;224(3):342-7; discussion 347-9.</citation>
    <PMID>8813262</PMID>
  </reference>
  <reference>
    <citation>Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000 Apr;135(4):409-14; discussion 414-5.</citation>
    <PMID>10768705</PMID>
  </reference>
  <reference>
    <citation>Mitchem JB, Hamilton N, Gao F, Hawkins WG, Linehan DC, Strasberg SM. Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J Am Coll Surg. 2012 Jan;214(1):46-52. doi: 10.1016/j.jamcollsurg.2011.10.008.</citation>
    <PMID>22192922</PMID>
  </reference>
  <reference>
    <citation>Ome Y, Hashida K, Yokota M, Nagahisa Y, Michio O, Kawamoto K. Laparoscopic radical antegrade modular pancreatosplenectomy for left-sided pancreatic cancer using the ligament of Treitz approach. Surg Endosc. 2017 Nov;31(11):4836-4837. doi: 10.1007/s00464-017-5561-6. Epub 2017 Apr 13.</citation>
    <PMID>28409377</PMID>
  </reference>
  <reference>
    <citation>Cao F, Li J, Li A, Li F. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: A systemic review and meta-analysis. BMC Surg. 2017 Jun 5;17(1):67. doi: 10.1186/s12893-017-0259-1. Review.</citation>
    <PMID>28583142</PMID>
  </reference>
  <reference>
    <citation>Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg. 2007 Feb;204(2):244-9. Epub 2007 Jan 4.</citation>
    <PMID>17254928</PMID>
  </reference>
  <reference>
    <citation>Park HJ, You DD, Choi DW, Heo JS, Choi SH. Role of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. World J Surg. 2014 Jan;38(1):186-93. doi: 10.1007/s00268-013-2254-8.</citation>
    <PMID>24166024</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 24, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Dai Menghua</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Radical Antegrade Modular Pancreatosplenectomy(RAMPS)</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Minimal Invasive</keyword>
  <keyword>ERAS</keyword>
  <keyword>Disease Free Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD is not avaiable, but statistical data is avaiable</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

